EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Effect of voxelotor on murine bone marrow and peripheral blood with hematopoietic progenitor cell mobilization for gene therapy of sickle cell disease

Avital Mendelson, Yunfeng Liu, Weili Bao, Patricia A Shi

Blood Cells, Molecules, and Diseases · 2024

DOI: 10.1016/j.bcmd.2024.102824 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Blood Cells, Molecules, and Diseases, 2024. Verfasst von Avital Mendelson und 3 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Stem Cell Biology and Engineering, New York Blood Center, New York, NY, USA. Electronic address: amendelson@nybc.org. Hauptthemen laut MEDLINE: Heterocyclic Compounds, Anemia, Sickle Cell, Hematopoietic Stem Cell Transplantation, Benzaldehydes. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In preparation for hematopoietic stem cell mobilization and collection, current ex vivo gene therapy protocols for sickle cell disease require patients to undergo several months of chronic red cell transfusion. For health care equity, alternatives to red cell transfusion should be available. We examined whether treatment with GBT1118, the murine analog of voxelotor, could be a safe and feasible alternative to red cell transfusion. We found that 3 weeks of treatment with GBT1118 increased the percentage of bone marrow hematopoietic stem cells and upon plerixafor mobilization, the percentage of peripheral blood hematopoietic stem cells. Our data suggest that voxelotor should be further explored for its potential safety and utility as preparation for hematopoietic stem cell mobilization and collection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heterocyclic CompoundsAnemia, Sickle CellHematopoietic Stem Cell TransplantationBenzaldehydesPyrazinesHumansMiceAnimalsHematopoietic Stem Cell MobilizationBone MarrowHematopoietic Stem CellsPyrazolesGenetic TherapyGranulocyte Colony-Stimulating FactorNiacinamide

Stichwörter der Autor:innen

Bone marrowGene therapyHematopoietic stem cell mobilizationHematopoietic stem cellsPlerixaforSickle cell diseaseVoxelotor

Substanzen

GBT1118voxelotorHeterocyclic CompoundsPyrazolesGranulocyte Colony-Stimulating FactorBenzaldehydesNiacinamidePyrazines

Autor:innen und Institutionen

  • Laboratory of Stem Cell Biology and Engineering, New York Blood Center, New York, NY, USA. Electronic address: amendelson@nybc.org.
  • Laboratory of Complement Biology, New York Blood Center, New York, NY, USA. Electronic address: yliu@nybc.org.
  • Laboratory of Complement Biology, New York Blood Center, New York, NY, USA. Electronic address: wbao@nybc.org.
  • Clinical Research in Sickle Cell Disease, New York Blood Center, New York, NY, USA. Electronic address: pshi@nybc.org.

Förderung

  • NHLBI NIH HHS

Zitieren

APA

Mendelson, A., Liu, Y., Bao, W., & Shi, P. A. (2024). Effect of voxelotor on murine bone marrow and peripheral blood with hematopoietic progenitor cell mobilization for gene therapy of sickle cell disease. Blood Cells, Molecules, and Diseases. https://doi.org/10.1016/j.bcmd.2024.102824

Vancouver

Mendelson A, Liu Y, Bao W, Shi PA. Effect of voxelotor on murine bone marrow and peripheral blood with hematopoietic progenitor cell mobilization for gene therapy of sickle cell disease. Blood Cells, Molecules, and Diseases. 2024. doi:10.1016/j.bcmd.2024.102824

BibTeX
@article{Mendelson2024,
  author = {Mendelson, Avital and Liu, Yunfeng and Bao, Weili and Shi, Patricia A},
  title = {Effect of voxelotor on murine bone marrow and peripheral blood with hematopoietic progenitor cell mobilization for gene therapy of sickle cell disease},
  journal = {Blood Cells, Molecules, and Diseases},
  year = {2024},
  doi = {10.1016/j.bcmd.2024.102824}
}
Kostenlos starten →